Neuroleptic malignant syndrome: Difference between revisions

(Created page with "==Pathogenesis== Related to Dopamine Blockade in: Anterior Hypothalamus --> Hyperthermia Frontal Lobe --> AMS Nigrostriatal Pathways --> Rigidity Sympathetic Nervous System...")
 
 
(60 intermediate revisions by 11 users not shown)
Line 1: Line 1:
==Pathogenesis==
==Background==
*Life threatening neurologic emergency associated with the use of neuroleptic agents<ref>Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. Nov 15 2013</ref><ref>Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477-92</ref>
**Can occur with single dose, increasing dose, or same dose as usual <ref>Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H. and Whyte, I. M. (2003) ‘The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity’, QJM, 96(9), pp. 635–642. doi: 10.1093/qjmed/hcg109</ref>
**Most often seen with "typical" high potency antipsychotics ([[haloperidol]])
***also occurs with newer "atypicals" ([[risperidone]], [[olanzapine]])
***antiemetics ([[metoclopramide]], [[promethazine]])
***withdrawal of anti-Parkinson medication
*Develops over 1-3 days
*Majority of deaths occur from complications of muscle rigidity
*Mortality rates up to 5 to 20% <ref>Shalev A. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.</ref>


==Clinical Features==
[[File:PMC3703349 CRIM.DENTISTRY2013-542130.002.png|thumb|Patient exhibiting NMS symptoms: hyperthermia, significant extrapyramidal symptoms, various autonomic symptoms, and impaired consciousness.]]
*Develops over 1-3 days
*Tetrad of:<ref>Gurrera RJ, Velamoor V, Cernovsky ZZ. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. Aug 22 2013</ref>
**[[Altered mental status]] - [[agitated delirium]] progressing to stupor/[[coma]]
**Muscle rigidity - generalized, "lead pipe" rigidity
**[[Hyperthermia]] >38C (87%); >40C (40%)
**Autonomic instability - [[tachycardia]], [[hypertension]], diaphoresis


Related to Dopamine Blockade in:
===Complications===
*[[Dehydration]]
*[[Electrolyte imbalance]]
*[[Acute renal failure]] ([[rhabdomyolysis]])
*[[Dysrhythmias ]]
*[[ACS]]
*[[Respiratory failure]]
**Chest wall rigidity, aspiration [[pneumonia]], [[PE]]
*[[DIC]]
*[[Seizure]] ([[hyperthermia]], [[electrolyte derangements]])
*[[Hepatic failure]]
*[[Sepsis]]


Anterior Hypothalamus --> Hyperthermia
==Differential Diagnosis==
*[[Serotonin Syndrome]]
**Serotonin syndrome more likely to have hyperreflexia, myoclonus, ataxia, nausea and vomiting, diarrhea
**Rigidity and hyperthermia, if present, is less severe than in NMS; more commonly presents with clonus and hyperreflexia
*[[Malignant Hyperthermia]]
**Distinguish by clinical setting (use of inhalational anesthetics or sux)
**Hyperthermia, muscle rigidity, and dysautonomia is similar to NMS though more fulminant
*[[Anticholinergic Toxicity]]
**Diaphoresis, rigidity, elevated CK are absent
**Flushing, mydriasis, bladder distension are common
*[[Sympathomimetics]]
**Rigidity is not seen


Frontal Lobe --> AMS
{{Movement disorder DDX}}
{{AMS and fever DDX}}


Nigrostriatal Pathways --> Rigidity
==Evaluation==
*Total CK
**Typically >1000
**Correlates with degree of rigidity
*CBC
**[[leukocytosis|WBC >10K]] is typical
*Chemistry
**May show [[hypocalcemia]], [[hypomagnesemia]], [[hyperkalemia]], [[metabolic acidosis]]
*[[Urinalysis]]
**Myoglobinuria (from rhabdo)
*[[LFTs]]
**Transaminitis
*[[head CT|CT]]/[[LP]]
**CSF may have mildly elevated protein


Sympathetic Nervous System --> Autonomic Instability
{{Serotonin syndrome vs neuroleptic malignant syndrome}}


== ==
==Management==
*The causative agent should be stopped
*Discontinue all dopamine blocking agents
*If precipitant is a dopaminergic therapy (L-dopa or Carbidopa) it can be restarted later at lower doses as an outpatient


===Supportive Care===
*Agitation should be controlled with [[Benzodiazepines]]
**Lorazepam 2 mg IV q5 min until agitation and muscle rigidity resolves
*[[Fluid resuscitation]]
*Cooling measures
*Intubation and paralysis for severe cases, chest wall rigidity or respiratory failure
**Use NON-DEPOLARIZING paralytic agent


==Diagnosis==
===Directed Medical Therapy<ref>Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20 </ref>===
''Controversial with unclear and disputed efficacy''
*[[Dantrolene]] (skeletal muscle relaxant) - Consider only in patients with severe rigidity
**May cause hepatotoxicity in patients with liver disease
**0.25-2mg/kg IV q6-12hr, max dose 10mg/kg/day
*[[Bromocriptine]] (dopamine agonist)
**2.5mg PO q6-8hr, max dose 40mg/day
*[[Amantadine]] (alternative to bromocriptine)
**100mg PO initially; titrate up as needed to max dose 200mg q12hr


===Electroconvulsive Therapy===
*Limited case series suggest that ECT can be effective in NMS refractory to pharmacotherapy<ref>Morcos N et al., Electroconvulsive therapy for neuroleptic malignant syndrome: a case series. J ECT. 2019.</ref>


Mortality of 10-20%
==Disposition==
*Admit, usually to ICU


Classic Tetrad of Symptoms:
==See Also==


1) Altered Mental Status


2) Muscular Rigidity
==References==
<references/>


3) Fever
[[Category:Psychiatry]]
 
[[Category:Toxicology]]
4) Autonomic Instability
 
 
Clinical History
 
Drug Exposure:
 
Typical high potency antipsychotics (haloperidol)
 
Atypical neuroleptics (risperidone, olanzapine, clozapine)
 
Antiemetics (metochlopromide, promethazine)
 
Withdrawal of anti-Parkinson medication
 
 
Timing:
 
Symptoms typically occur within 4-14d following initiation of med or an increase in dosing; can occur years after initiating therapy
 
 
Laboratory Examination (non-specific):
 
Total CK > 1000
 
WBC > 10K
 
Mildly elevated LDH, LFTs
 
Renal Insufficiency
 
CSF with mildly elevated Protein
 
Low Serum Iron
 
 
Diagnostic Criteria:
 
DSM-IV:
 
Recent administration of antipsychotic
 
Elevated Temp (> 40C)
 
Muscle Rigidity
 
Atleast 2 other signs/symptoms or lab findings c/w NMS
 
 
DDx
 
Delirium tremens
 
Heat Stroke (altered CNS, temp >40)
 
Meningitis
 
Malignant Hyperthermia (genetic d/o; 1h post general anesthetic; hyperthermia up to 45deg C, rigidity, tachy, skin cyanosis with mottling)
 
 
==Treatment==
 
 
ABCs
 
Stop the Offending Agent
 
Aggressive Cooling Measures
 
Fluid Resuscitation
 
Supportive Care
 
Benzos: for agitation
 
 
Dantrolene:
 
direct skeletal muscle relaxant
 
(Showed improvement in 80% cases)
 
Dosage: 10mg/kg per day
 
Relative Contraindication in pts on CCB (can lead to cardiovascular collapse)
 
 
Bromocriptine:
 
dopamine agonist to counteract central blockade
 
Max: 40mg/day
 
 
Amantadine:
 
dopamine agonist and anticholinergic agent
 
Max 400mg/day
 
 
Consider ECT
 
 
Retrospective analysis: suggests pts on dantrolene +/- bromocriptine have a faster recovery (9days vs 12Days)
 
 
Woodbury Stages
 
Incorporates severity of disease with treatment
 
(I-III: supportive care +/- benzos)
 
 
Stage IV (Moderate NMS): All four features present
 
TX: benzos, bromocriptine
 
 
Stage V (Severe NMS) Tetrad with more severe hyperthermia
 
TX: benzos, dantrolene, bromocriptine, consider ECT
 
 
==Complications==
 
 
arrhthmias, renal failure, seizures, pneumonia, DIC, death
 
 
Prognosis==
 
 
Most resolve within 2 weeks, without long term sequelae
 
Poorer prognosis in those with high peak and/or long duration of hyperthermia
 
 
==Potential Pitfalls==
 
 
Overlooking the AMS in a “psych pt”
 
Delay in obtaining rectal temp
 
Use of physical restraints
 
Isometric contractions leads increased metabolism, worsening rhabdo and hyperthermia
 
Use of high potency antipsychotics in the ER
 
 
==Source==
 
 
Pani 6/2009 based on Rosen's
 
 
 
 
[[Category:Neuro]]

Latest revision as of 22:44, 21 September 2022

Background

  • Life threatening neurologic emergency associated with the use of neuroleptic agents[1][2]
  • Develops over 1-3 days
  • Majority of deaths occur from complications of muscle rigidity
  • Mortality rates up to 5 to 20% [4]

Clinical Features

Patient exhibiting NMS symptoms: hyperthermia, significant extrapyramidal symptoms, various autonomic symptoms, and impaired consciousness.

Complications

Differential Diagnosis

  • Serotonin Syndrome
    • Serotonin syndrome more likely to have hyperreflexia, myoclonus, ataxia, nausea and vomiting, diarrhea
    • Rigidity and hyperthermia, if present, is less severe than in NMS; more commonly presents with clonus and hyperreflexia
  • Malignant Hyperthermia
    • Distinguish by clinical setting (use of inhalational anesthetics or sux)
    • Hyperthermia, muscle rigidity, and dysautonomia is similar to NMS though more fulminant
  • Anticholinergic Toxicity
    • Diaphoresis, rigidity, elevated CK are absent
    • Flushing, mydriasis, bladder distension are common
  • Sympathomimetics
    • Rigidity is not seen

Movement Disorders and Other Abnormal Contractions

Altered mental status and fever

Evaluation

Serotonin syndrome vs Neuroleptic malignant syndrome

  • History of a new serotonergic drug or a dose increase of a serotonergic drug are helpful
  • Serotonin syndrome is usually much more acute in onset than NMS which may develop over days or weeks
  • Presence of ‘lead pipe’ rigidity is typical of NMS, while serotonin syndrome typically manifests with tremor and hyperreflexia
  • Elevations in CK, LFTs, and WBC, coupled with a low iron level, distinguishes NMS from serotonin syndrome among patients taking both neuroleptic and serotonin agonist medications simultaneously

Management

  • The causative agent should be stopped
  • Discontinue all dopamine blocking agents
  • If precipitant is a dopaminergic therapy (L-dopa or Carbidopa) it can be restarted later at lower doses as an outpatient

Supportive Care

  • Agitation should be controlled with Benzodiazepines
    • Lorazepam 2 mg IV q5 min until agitation and muscle rigidity resolves
  • Fluid resuscitation
  • Cooling measures
  • Intubation and paralysis for severe cases, chest wall rigidity or respiratory failure
    • Use NON-DEPOLARIZING paralytic agent

Directed Medical Therapy[6]

Controversial with unclear and disputed efficacy

  • Dantrolene (skeletal muscle relaxant) - Consider only in patients with severe rigidity
    • May cause hepatotoxicity in patients with liver disease
    • 0.25-2mg/kg IV q6-12hr, max dose 10mg/kg/day
  • Bromocriptine (dopamine agonist)
    • 2.5mg PO q6-8hr, max dose 40mg/day
  • Amantadine (alternative to bromocriptine)
    • 100mg PO initially; titrate up as needed to max dose 200mg q12hr

Electroconvulsive Therapy

  • Limited case series suggest that ECT can be effective in NMS refractory to pharmacotherapy[7]

Disposition

  • Admit, usually to ICU

See Also

References

  1. ↑ Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. Nov 15 2013
  2. ↑ Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477-92
  3. ↑ Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H. and Whyte, I. M. (2003) ‘The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity’, QJM, 96(9), pp. 635–642. doi: 10.1093/qjmed/hcg109
  4. ↑ Shalev A. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.
  5. ↑ Gurrera RJ, Velamoor V, Cernovsky ZZ. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. Aug 22 2013
  6. ↑ Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20
  7. ↑ Morcos N et al., Electroconvulsive therapy for neuroleptic malignant syndrome: a case series. J ECT. 2019.
Retrieved from "https://www.wikem.org/w/index.php?title=Neuroleptic_malignant_syndrome&oldid=366388"